Combinatorial therapeutics in high-risk infant acute lymphoblastic leukaemia

高危婴儿急性淋巴细胞白血病的联合治疗

• 批准号: nhmrc : GNT1142627
• 负责人: Dr Rishi Kotecha
• 金额: $ 34.09万
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/combinatorial-therapeutics-high-lymphoblastic-leukaemia/1348463
• 关键词: Combinatorial; therapeutics; risk; infant; acute

Modern therapies for children with leukaemia are curative in more than 90%. In contrast, survival for infants less than one year of age at the time of diagnosis is less than 50%. Better therapies are desperately needed. From laboratory testing we have discovered effective novel cancer drugs, which are not currently used for treatment of babies with leukaemia. We will evaluate novel drug combinations and test them in model systems, such that they can be fast-tracked to the clinic.

对儿童白血病的现代疗法治愈率超过90%。相比之下，在诊断时小于一岁的婴儿存活率低于50%。我们迫切需要更好的治疗方法。从实验室测试中，我们发现了有效的新型抗癌药物，目前还没有用于治疗患有白血病的婴儿。我们将评估新的药物组合，并在模型系统中进行测试，这样它们就可以快速进入临床。